Evidence map›Paper›PMID 28241095›Full record

ReviewCancer2017

Immune checkpoint inhibitors in challenging populations.

Douglas B Johnson, Ryan J Sullivan, Alexander M Menzies

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04115410 (PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events), which is not on this map. Cited by 192 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04115410 unknown statusnot on this mapstarted 2020, after this paper: background citation

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

TypeobservationalSponsorSungkyunkwan UniversityRan2020 to 2021Enrolled4,724ConditionsCarcinoma, Non-Small-Cell Lung, Immune-Related Adverse EventsArmsPD-1 inhibitor, Chemotherapy Drugs, Cancer
3 · Its place in the literature

Who cites it

192 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

132 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Douglas B JohnsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-6390-773X
Ryan J SullivanDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Alexander M MenziesDepartment of Medicine, Melanoma Institute Australia, University of Sydney Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.

Funding

Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
Enhancing Translational Science via Prospective InvestigationK24CA172355 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RATHMELL, WENDY KIMRYN · 2013 to 2017
$870k
Predicting and profiling long-term survival after immune checkpoint inhibitionK23CA204726 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B · 2016 to 2020
$756k
NCI NIH HHS K12 CA090625NCI NIH HHS K23 CA204726NCI NIH HHS K24 CA172355
6 · The paper itself

Abstract

Immune checkpoint inhibitors, including those targeting the programmed cell death 1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice have not qualified for or have been seriously underrepresented in immune checkpoint inhibitor clinical trials. Thus, a major gap in knowledge regarding the safety and efficacy of these agents persists in many populations, even after regulatory approval. To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical populations to assist both academic and community oncologists in treatment decision making. Specifically, this review focuses on the safety and activity of immune checkpoint inhibitors in patients with autoimmune disorders, organ transplant patients, patients with chronic viral infections, patients with ongoing immunosuppressant use, patients with organ dysfunction, pregnant patients, patients with brain metastases, patients at extremes of age, and patients with an impaired functional status. Cancer 2017;123:1904-1911. © 2017 American Cancer Society.

Indexed as

Age FactorsAntibodies, MonoclonalAntineoplastic AgentsAutoimmune DiseasesB7-H1 AntigenBrain NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellCarcinoma, Squamous CellCTLA-4 AntigenFemaleGraft RejectionHead and Neck NeoplasmsHepatitis B, ChronicHepatitis C, ChronicHIV InfectionsAntibodies, MonoclonalAntineoplastic AgentsB7-H1 AntigenCTLA-4 AntigenImmunosuppressive AgentsIpilimumabNivolumabProgrammed Cell Death 1 Receptorautoimmuneelderlyipilimumabnivolumaborgan dysfunctionpediatricspembrolizumabpregnancytransplant

Identifiers

PMID28241095
PMCPMC5445005

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.